Biogen gains recombinant factor VIII, factor IX manufacturing rights
Sobi and Biogen have announced an agreement under which Biogen assumed full development responsibilities and costs, as well as manufacturing rights of long-lasting recombinant factor VIII and factor IX.
Under the agreement, the cross-royalty rates were reduced and commercial rights for certain territories were changed.
Sobi will have commercial rights in Europe, Russia, Turkey and certain countries in the Middle East (the Sobi territory).
Biogen has commercial rights for North America and for rest of the world markets outside of Europe, Russia, Turkey and certain countries in the Middle East (the Biogen Direct territory).
Following Biogen's submission of MAA to EMA for each program, Sobi may opt to take over final approval, pre-launch and commercialization activities in its territory at $10m per program.
To effect Sobi's reimbursement to Biogen for each program, the cross-royalty structure for direct sales in each company's respective territories will be adjusted until the consideration is paid in full.
Related Insight
Suppliers Directory
Olink Bioscience - Biomolecular Analysis in Research and Diagnostics
Olink Bioscience is commercializing cutting-edge technologies for analysis of proteins and nucleic acids revealing new insights into basic science, drug development and diagnostics. The products are available worldwide through a network of distributors and through the Olink webshop. The Duolink® product line enables users to visualize and quantify individual proteins, their interactions and modifications, in unmodified cells and tissues. Proseek® is an open assay development reagent kit for analyzing proteins in only 1 µl of serum or plasma sample with high sensitivity.
Production & Manufacturing > Manufacturing > Suppliers
SCM Pharma - Sterile Manufacturing and Aseptic Filling of Liquids, Gels and Powders (Including Cytotoxic and C14 Radiolabled Drugs) Into Vials, Ampoules, Syringes and Cartridges
SCM Pharma is UK-based pharmaceutical contract manufacturing organisation (CMO) that works with clients progressing drugs through clinical trials and others that require low volume commercial supply of niche licensed products.
Production & Manufacturing > Manufacturing > Suppliers
Heraeus - Highly Potent Active Pharmaceutical Ingredients
Heraeus, the precious metals and technology group headquartered in Hanau, Germany, is a global, private company with over 155 years of tradition. Our businesses include precious metals, sensors, biomaterials and medical products, dental products, quartz glass, and specialty light sources.
Production & Manufacturing > Manufacturing > Suppliers
Sofrigam - Industrial Insulated and Refrigerated Packaging
Sofrigam designs and qualifies isothermal and refrigerated packaging enabling the transport of heat sensitive products in non-refrigerated vehicles.
Production & Manufacturing > Manufacturing > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Manufacturing Intelligence
Finding the Right Contract Manufacturer
Published by Vetter Pharma International
Production & Manufacturing > Manufacturing > White Papers
Enabling Drug Delivery Deal Making
Published by Aveva Drug Delivery Systems
Production & Manufacturing > Manufacturing > White Papers
Heraeus Expertise and Services
Published by Heraeus
Production & Manufacturing > Manufacturing > White Papers
Capsule Testing: Breaking-Force Tests for Empty and Filled Hard Capsules and Softgels
Published by Dr Schleuniger Pharmatron
Production & Manufacturing > Manufacturing > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.